BioSpace News Archive

ANNOVERA® prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period

ANI Pharmaceuticals, Inc. announced business highlights and financial results for the three and six months ended June 30, 2020.

Baudax Bio, Inc., a pharmaceutical company focused on therapeutics for acute care settings, announced that the Centers for Medicare and Medicaid Services established a new permanent J-code for ANJESO injection facilitating reimbursement in the hospital outpatient, ambulatory surgery center and physician office settings of care.

- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the virtual 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Wednesday, August 12, 2020 at 4:30PM EDT. This meeting is being held

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40 th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com.

Regulatory and Clinical Progress in MLD, MPS-I and MPS-IIIA Illustrate Execution in Neurometabolic Disorders; EU Regulatory Decision for Libmeldy ™ Expected in 2H 2020 MolMed and GSK Agreements Provide Near-term Manufacturing Capacity and Highlight Future Innovations Near-term Financial Position Secure with Cash and Investments of ~$230M and Runway into 2022 BOSTON and LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: BTIG Virtual Biotechnology Conference 2020 Tuesday, August 11, 2020 at 1:00 p.m. ET Canaccord Genuity 40 th Annual Growth Conference Thursday, August 13, 2020 at 1:30

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and CBN, announces its relationship with Ezzey Digital Marketing Agency to launch its new proprietary aerosol inhaler and lifestyle brand to be called nhāler. RTSL digital infrastructure built

Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019 Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019 Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 Million EWING, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today reported operating and financial results for the second quar

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a virtual fireside chat at the Canaccord Genuity 40th Annual Growth Conference. Presentation Details: Event: Canaccord Genuity 4